Maurizio Fava, MD
Co-Founder, SAB Member
Stephen Haggarty, PhD
SAB Member
Dr. Stephen J. Haggarty leads Psy Therapeutics’ Dementia program and is a fully engaged member of the Scientific Advisory Board. His deep understanding of neuroplasticity has guided Psy’s discovery of potential novel targeted therapeutics for the treatment and prevention of Dementia.
Dr. Haggarty has been a member of Harvard Medical School/Massachusetts General Hospital (MGH) faculty since 2006, with current appointments in the Department of Neurology and Psychiatry. He is an Associate Professor of Neurology at Harvard Medical School, an Associate Neuroscientist at MGH and Director of the MGH Chemical Neurobiology Laboratory within the Center for Genomic Medicine. Additionally, he serves as an Associate Member of the Broad Institute and Affiliate Faculty Member of the Harvard Stem Cell Institute.
In 2017, Dr. Haggarty was named the Stuart & Suzanne Steele MGH Research Scholar. His translational research program focuses on understanding and targeting mechanisms of neuroplasticity in health and diseases, with a major emphasis on the characterization of patient-derived ex vivo models of CNS disorders and their use in drug discovery.
He also serves on the Scientific Advisory Board of multiple companies advancing novel targeted therapeutics at the interface of neurology and psychiatry. Dr. Haggarty completed his PhD in the Department of Chemistry & Chemical Biology at Harvard University.
